ABOUT MICROBIRA

Microbira Ltd which was founded in 2019 is based in the UK. Microbira focuses on utilising artificial intelligence coupled with Fourier Transform Infrared (FTIR) spectroscopy to enhance the efficiency of healthcare delivery. Our solution results in creating reagent free, rapid, low-cost in vitro diagnostic (IVD) tools for clinical and research usage.

At Microbira, we revolutionise microorganism identification through infrared technology and advanced software solutions. By leveraging FTIR spectroscopy and machine learning, we provide affordable, accessible tools for healthcare providers, researchers, and communities. Our goal is to fill market gaps, enable rapid antimicrobial resistance detection, and improve strain typing, all while reducing healthcare disparities and ensuring better health outcomes worldwide.

COMPANY HISTORY

2019

Founded

2021

MAAP-IR software UKCA marked

2022

Onset of international multicenter clinical validation study

2024

MAAP-IR performance upgrade and is commercial ready

2025

Expansion and further optimisation

Microbira Ltd, founded in 2019 and based in the UK, utilises AI and FTIR spectroscopy to develop reagent-free, rapid, low-cost IVD tools for healthcare and research. In 2020, we began developing the MAAP-IR web application, which achieved UKCA Class 1 certification in late 2021. Following successful clinical validation with the NHS and international partners, MAAP-IR was updated and made commercially available in the UK by the end of 2024. Microbira is pursuing additional regulatory clearances, while expanding into India to support its growing healthcare and research sectors. In 2025, we have registered our business in in India as Microbira India Pvt Ltd.

OUR MISSION

Our mission is to revolutionize microorganism identification through utilising infrared technology coupled with advanced and innovative software solutions. We aim to provide accurate, easy-to-use, and accessible identification tools that empower healthcare providers, researchers, and industries to make informed decisions for better health outcomes and scientific advancement.

Our vision is to empower healthcare providers, researchers, and communities with affordable and accessible solutions for microorganism identification. By leveraging FTIR spectroscopy and machine learning, we aim to fill critical gaps in the market, enabling rapid detection of antimicrobial resistance and providing accurate strain typing. We are dedicated to reducing healthcare disparities and ensuring that advanced diagnostic tools are available to all, improving health outcomes worldwide.

OUR VALUES

OUR TEAM

Marianne Ismail

CEO
Marianne specializes in strategic planning, financial management, and business communication, with a proven track record in improving profitability and restructuring portfolios. Holding a master’s in Clinical Microbiology and Infectious Diseases from Edinburgh University, her expertise has helped Microbira secure investment, collaborate with UK institutions, and shape its future direction.
Linkedin

Lisa Lam, PhD

Director of Science and Technology
Lisa has a multidisciplinary background in food sciences, clinical microbiology, data sciences, and project management, with experience leading several social entrepreneurial projects. She completed her Ph.D. in Clinical Microbiology with a focus on biotechnology at McGill University. At Microbira, Lisa leads various initiatives in research and development.
Linkedin

Azeem Hanif

Business Development & Marketing Manager
Azeem has 20+ years of experience in sales, distribution, and project management, with a focus on the Pathology market. Starting as a Laboratory Technician, he later transitioned to commercial roles across the UK, Ireland, and Northern Europe. His technical expertise and understanding of customer needs drive meaningful partnerships and support, fueling innovation and new business.
Linkedin

Anushka Barthwal

Project Manager Assistant
Anushka has an academic background in Cancer Biomedicine from UCL, with experience in microbiology, bioinformatics, and clinical research. At Microbira, she is involved in developing collaborative and grant-funded projects. She is passionate about bringing innovative healthcare solutions to those who need them most.
Linkedin

Beverly Scott

Regulatory Affairs
Beverly is an expert in regulatory framework, specializing in software as a medical device, and digital health sectors. With extensive experience, she provides tailored solutions to navigate complex regulations and ensure compliance of Microbira's products.
Linkedin

Claire Hardie

Marketing and Public Relations
Claire has a background in commercial strategy, healthcare, and medical imaging, with expertise in marketing, business growth, and partnership development. She holds an MSc in Radiotherapy & Oncology from Sheffield Hallam University. At Microbira, Claire leads marketing efforts, brand development, and business expansion, leveraging her clinical and commercial experience to drive strategic initiatives.
Linkedin

OUR ADVISORY TEAM

Professor Walter Nimmo, Chairman

Dr. Nimmo is a retired distinguished professor in anaesthetics at Sheffield University. In 1988 Nimmo set up Inveresk Clinical Research that eventually became a market leader in clinical research and drug testing which was then sold to Charles River Laboratories in 2004.

PNG_logo_1 (1)

Ian Gray, Non-executive Director

A chartered accountant and previous director of Candover Investments plc. a British-based, private equity firm which specialises in arranging and leading large buyouts and buy-ins.

Mark Holleran, General counsel

Mark Holleran is the founder of The Lithium Capital Team, he is a highly experienced and well connected corporate finance and business advisor, having twice been shortlisted at the North West Business Insider Awards as well as being a practising solicitor in England.

OUR COLLABORATORS